Clodronate Liposome

Product Details

Creative Biolabs proudly offers clodronate liposomes. Clodronate liposomes are composed of clodronate molecules encapsulated in neutral liposomes, which are able to achieve the macrophage depletion after a single intravenous or intraperitoneal administration. Clodronate molecules encapsulated in small liposomes present superior activity, physical and chemical stability.

Liposomes are artificially prepared lipid vesicles that contain concentric phospholipid bilayers entrapping aqueous compartments. They are widely used to encapsulate strongly hydrophilic molecules in aqueous solutions, such as clodronate. Clodronate is a type of non-toxic bisphosphonate, and freely solved clodronate will not cross liposomal or cellular phospholipid membranes. After injection, bilayers of the liposomes can be ingested and digested by the lysosomal phospholipases in the macrophage to release clodronate and accumulate intracellularly. Once a certain intracellular concentration is reached, clodronate can induce the irreversible damage and apoptosis of macrophage. Using this method, clodronate liposomes have been used in many application studies such as the suppression of macrophage activity in various models of autoimmune diseases, transplantation, neurological disorders and gene therapy.

If you are finding more information about our clodronate liposome products, please feel free to contact us. We also provide custom-made liposomes to your specifications.

For Research Use Only. Not For Clinical Use

Technical Note

1. When clodronate liposomes come into contact with phagocytic cells, the cells react as if they were invading particles. This action results in the removal of the liposomes and the introduction of clodronate into the cell, initiating cell death. Unencapsulated clodronate cannot initiate such action.
2. Control liposomes, devoid of clodronate, when ingested by phagocytic cells, lead to reactions like cytokine secretion and a temporary pause in phagocytic activity without causing cell death.
3. Sterility is crucial when accessing the product. It shouldn't be used past the 60-day mark post-receipt and must be slowly turned before use to ensure uniform dispersion.
4. Staff must exhibit care during injections, and adverse reactions require a decreased infusion rate.
5. Mannosylated liposomes need a significant escape from first-pass uptake by the liver and spleen to interact with mannose-receptor-positive cells. Such escape is achieved through a reticuloendothelial system (RES) blockade, wherein a sufficient quantity of liposomes pre-doses the animal, temporarily saturating phagocytic cells.
6. Liposomes could bind opsonin, suggesting that RES blockade might involve serum depletion of complement and other opsonins. Serum reduction of solvable mannose-receptors may increase the mannose-receptor-liposome interaction.
7. Researchers should be ready for high mortality rates among immunodeficient mice when using clodronate liposomes. Additional animals may be required due to high mortality rates. Special attention is required to prevent opportunistic infections post-liposome administration.
8. Any infusion-related adverse reactions should be monitored for potential effects on experimental results.
9. Liposomes should be stored at 4°C and must never be frozen.

Publish Data

Doxorubicin-liposome combined with clodronate-liposome inhibits hepatocellular carcinoma through the depletion of macrophages and tumor cells
International Journal of Pharmaceutics

Authors: Zhang H, Sheng D, Han Z, et al.

Co-administration of clodronate and doxorubicin liposomes suppresses hepatic progenitor activation and enhances tumor drug delivery by macrophage depletion, curbing hepatocellular carcinoma growth.

Fig. 1 Co-administration of clodronate and doxorubicin liposomes

FAQs

Resources

For Research Use Only. Not For Clinical Use